University of Texas, El Paso Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2019
NCT03981523
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

The University of Texas at El Paso | The University of Texas at El Paso (UTEP) | University of Texas, El Paso

Active Ingredients

Drugs in Phase 2 Trials (2)

benznidazole (Rochagan) (1 trial)

nifurtimox (Lampit) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chagas Disease (Phase 2)

Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2